Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
Date:8/7/2008

n 68,216 111,119

Total liabilities 1,837,350 1,535,435

Commitments and Contingencies

Stockholders' Equity

Preferred stock, authorized 5,000,000 shares,

$.01 par value, none issued or outstanding - -

Common stock, authorized 100,000,000 shares,

$.001 par value, 41,130,270 and 40,991,385

issued and outstanding as of June 30, 2008,

and December 31, 2007, respectively 41,130 40,991

Additional paid-in capital 70,601,489 69,945,666

Accumulated deficit (61,940,977) (57,834,638)

Total stockholders' equity 8,701,642 12,152,019

$10,538,992 $13,687,454

SCOLR Pharma, Inc.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007

Revenues

Licensing fees $- $- $- $173,077

Royalty income 279,571 422,056 545,126 747,676

Research and

development income - - - 621,222

Total revenues 279,571 422,056 545,126 1,541,975

Operating expenses

Marketing and selling 191,047 225,374 428,739 475,256

Research and

development 1,197,321 1,377,499 2,080,533 3,173,374

General and

administrative 1,062,646 1,112,244 2,294,930 2,288,742

Total operating

expenses 2,451,014 2,715,11
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... XIFIN Inc., the leading provider of revenue ... that XIFIN,s CEO and Executive Chairman, Lale ... College Conference in New Orleans on April ... executives, laboratory administrators and pathologists from many ...
... friendlyHOUSTON, April 14 US Oncology, Inc., supporting the nation,s ... Web site, usoncology.com . In order to ... usoncology.com is part of a new branding effort ... aspect of cancer care. , , For the ...
... field of medical microbiology, biodefense and pathogens to febit, ... and HEIDELBERG, Germany, April 14 febit ... Ph.D., for its Scientific Advisory Board. Dr. Keim ... Division at TGen (The Translational ...
Cached Biology Technology:XIFIN Inc. CEO to Speak at Executive War College Conference 2XIFIN Inc. CEO to Speak at Executive War College Conference 3US Oncology Launches New Web Site 2US Oncology Launches New Web Site 3US Oncology Launches New Web Site 4US Oncology Launches New Web Site 5US Oncology Launches New Web Site 6Paul Keim Appointed to febit's Scientific Advisory Board 2
(Date:10/25/2014)... 22, 2014 This report covers the specifics ... space in heavy pursuit of research due to its ... compared to other RNA components. miRNA,s non-coding nature and ... candidate for use as a biomarker for a variety ... and diagnostics for the advancement in therapeutic development. Furthermore ...
(Date:10/22/2014)... -- Leading identity analyst firm Acuity Market Intelligence forecasts that ... will have a chip-based National eID card, including near-complete ... Asia , with its vast population, is ... 60% of all National eID cards issued between 2014 ... National eID Industry Report: 2014 Edition" — ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... In a paper being presented in two American ... joint Estonian-French team demonstrated "for the first time ... suggesting that mitochondria may mechanically regulate nuclear function." ... over 10 years, reported that it recently "found ...
... of biology's most fundamental questions ?why males produce sperm ... a breakthrough that could lead to improved infertility treatment, ... led by Dr Josephine Bowles and Professor Peter Koopman ... of Queensland, has discovered that derivatives of Vitamin A ...
... Virginia Tech in the United States have determined the ... production xanthurenic acid (XA) in Anopheles gambiae, the malaria ... sexual reproduction of the malaria parasite (Plasmodium falciparum) in ... could be an avenue for development of drugs and ...
Cached Biology News:First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown 2First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown 3One big biology question solved 2Oxidation defense in mosquitoes benefits malaria parasite 2
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: